Haemophilia in the developing countries: the Iranian experience

Abstract

IntroductionManagement of haemophilia and inherited bleeding disorders is a major challenge especially in developing countries, because of a shortage or absence of products, the cost and the infrastructural health problems. Development of local expertise which results in an improved outlook and reduction in mortality and morbidity in these countries can be helpful for advocators in other developing countries. However, very little information on demography and organizational models for haemophilia care in developing countries are available in the literature. Our aim is a comprehensive report of haemophilia status and its management in Iran.Material and methodsThe Management Center of Transplantation and Special Diseases (MCTSD) of the Ministry of Health of Iran decided to carry out a complete review and compilation of all of the published or available data about patients with haemophilia (PWH) in Iran: their health status, their management planning, organizations, treatment products, facilities and care problems during 2007.Results6496 patients with congenital bleeding disorders were registered. Most of them had haemophilia A and B and von Willebrand disease (vWD). However, rare bleeding disorders are seen more than expected. Inhibitor development is 14–28%. There are different data about virological status of PWH. Factor products and facilities are fairly available with more than 1.5 units per capita of inhabitant factor consumption.ConclusionsA national formulary based on facilities of the country should be considered and followed by collaboration among the Ministry Of Health, universities and non-governmental organizations.

Clinico-epidemiological profile of hemophilia with special reference to development of inhibitors in Indian scenario: a crosses sectional study at tertiary care centre in north India

“…6,8,10 Studies from other parts of world shows a higher prevalence ranging from 24-30%. 6,9,11,12 Keeping these facts in mind it is necessary to identify patients with inhibitors and provide treatment facilities to them so these patients can lead a productive life because management of Hemophilia patients with inhibitor is very difficult.…”

Is there any association between leptin levels and bone mineral density in haemophiliac men?

“…They are characterized by intra-articular bleeding which leads to severe arthropathy [1]. Haemophilia A and B have been associated with increased incidence of bone disease (osteopenia or osteoporosis), about 67-86% in a few studies [2–6].…”

Descriptive Epidemiology and Complications of Haemophilia in Assiut, Egypt

“…of their patients were HCV positive and none of them had serological evidences of hepatitis B virus, and also with Eshghi et al [12] who represented in his work the prevalence of HCV infections among studied hemophilic patients was 15.6% and prevalence of HBV was 8%.This can be explained by the increased awareness and use of safe virus inactivated plasma transfusions and factor concentrates. The current study showed that, the most common line of treatment used in our hemophilic patients was on demand factor concentrate treatment used by 54 patients representing 72% of studied group and prophylaxis treatment used by 18 patients representing 24% of studied group and only 3 patients were without treatment representing 4%.…”